These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24595405)

  • 21. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
    Gerlier L; Lamotte M; Awada A; Bosly A; Bries G; Cocquyt V; Focan C; Henry S; Lalami Y; Machiels JP; Mebis J; Straetmans N; Verhoeven D; Somers L
    BMC Cancer; 2010 Nov; 10():642. PubMed ID: 21092320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens.
    Weycker D; Li X; Edelsberg J; Barron R; Kartashov A; Xu H; Lyman GH
    Support Care Cancer; 2014 Dec; 22(12):3275-85. PubMed ID: 25082364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.
    Fernandes R; Mazzarello S; Stober C; Ibrahim MFK; Dudani S; Perdrizet K; Majeed H; Vandermeer L; Shorr R; Hutton B; Fergusson D; Gyawali B; Clemons M
    J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 30241156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
    Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
    Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
    Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
    Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey.
    Link H; Kerkmann M; Holtmann L; Ortner P;
    Support Care Cancer; 2019 Apr; 27(4):1459-1469. PubMed ID: 30374765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort study.
    Kwok CCH; Wong WH; Chan LL; Wong SPY; Wang F; Wong MCS; Tse SLA
    Hong Kong Med J; 2022 Dec; 28(6):438-446. PubMed ID: 36261264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.
    Link H; Nietsch J; Kerkmann M; Ortner P;
    Support Care Cancer; 2016 Jan; 24(1):367-376. PubMed ID: 26081593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
    Xu B; Tian F; Yu J; Song Y; Shi J; Zhang B; Zhang Y; Yuan Z; Wu Q; Zhang Q; Nan K; Sun Q; Li W; Hu J; Bi J; Meng C; Dai H; Jiang H; Yue S; Cao B; Sun Y; Wang S; Tong Z; Shen P; Wu G; Tang L; Deng Y; Jia L; Shen K; Zhuang W; Xie X; Wu Y; Chen L
    Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):23-7. PubMed ID: 26796802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
    Martín M; Lluch A; Seguí MA; Ruiz A; Ramos M; Adrover E; Rodríguez-Lescure A; Grosse R; Calvo L; Fernandez-Chacón C; Roset M; Antón A; Isla D; del Prado PM; Iglesias L; Zaluski J; Arcusa A; López-Vega JM; Muñoz M; Mel JR
    Ann Oncol; 2006 Aug; 17(8):1205-12. PubMed ID: 16766587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer.
    Nomura H; Hatogai K; Maki Y; Mochizuki N; Tanaka M; Saito S; Daiko H; Kojima T; Kawasaki T
    Support Care Cancer; 2020 Apr; 28(4):1849-1854. PubMed ID: 31342165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
    Phua CE; Bustam AZ; Yusof MM; Saad M; Yip CH; Taib NA; Ng CH; Teh YC
    Asian Pac J Cancer Prev; 2012; 13(9):4623-6. PubMed ID: 23167391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University).
    Sakr H; Hamed RH; Anter AH; Yossef T
    Med Oncol; 2013 Mar; 30(1):457. PubMed ID: 23322524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TAXTOX - a retrospective study regarding the side effects of docetaxel given as part of the adjuvant treatment to patients with primary breast cancer in Denmark from 2007 to 2009.
    Eckhoff L; Nielsen M; Moeller S; Knoop A
    Acta Oncol; 2011 Oct; 50(7):1075-82. PubMed ID: 21824038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
    Agiro A; Ma Q; Acheson AK; Wu SJ; Patt DA; Barron JJ; Malin JL; Rosenberg A; Schilsky RL; Lyman GH
    J Clin Oncol; 2016 Nov; 34(32):3872-3879. PubMed ID: 27646945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
    Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
    Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.
    Yerushalmi R; Goldvaser H; Sulkes A; Ben-Aharon I; Hendler D; Neiman V; Ciuraru NB; Bonilla L; Amit L; Zer A; Granot T; Rizel S; Stemmer SM
    PLoS One; 2014; 9(10):e107273. PubMed ID: 25330205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
    Kawahira M; Yokota T; Hamauchi S; Kawai S; Yoshida Y; Onozawa Y; Tsushima T; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
    Int J Clin Oncol; 2018 Dec; 23(6):1189-1195. PubMed ID: 29948238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer. Cooperative Group of Study and Treatment of Breast Cancer.
    Riccardi A; Brugnatelli S; Giordano M; Danova M; Pugliese P; Tinelli C; Klersy C; Richetti A; Fava S; Nastasi G; Rinaldi E; Fregoni V; De Monte A; Trotti G; Bovio A; Ascari E
    Tumori; 1998; 84(5):540-6. PubMed ID: 9862513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.